comprehensive epigenomics Services.

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Diagenode Inc for comprehensive epigenomics Services.

The NIAID Immunopathogenesis section requires comprehensive epigenomics services to understand the variable penetrance in patients with gerline CTLA4 mutations. Epigenomic services will provide information of biomarkers for ongoing clinical drug development and disease treatment that have shifted from the one-drug-for-all to targeted therapy trials.

Comprehensive epigenomic services included in this requirement are as follows; RNA sequencing, for low or degraded inputs including those from liquid biopsies, FFPE, exosomes, serum and plasma. This genetic screening / sequencing of epigenetic landscape will include solid bioinformatics analysis. Due to prior clinical studies and the integrity on on-going research, Diagenode Inc is the only vendor capable of meeting this clinical research requirement.

Place of delivery is Bethesda, MD 20892.

The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-RML-D-1980805) to Calvin Robinson at calvin.robinson@nih.gov, by 5:00 pm eastern standard time Monday, Sept, 14th 2019 . All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

.